Sanofi
SNY
500 hedge funds and large institutions have $7.77B invested in Sanofi in 2018 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 135 increasing their positions, 185 reducing their positions, and 52 closing their positions.
1,110% more call options, than puts
Call options by funds: $33.3M | Put options by funds: $2.75M
48% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 52
4% more funds holding
Funds holding: 480 → 500 (+20)
0.12% more ownership
Funds ownership: 14.17% → 14.29% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
2% less capital invested
Capital invested by funds: $7.95B → $7.77B (-$176M)
27% less repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 185
Top Buyers
Top Sellers
| 1 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$52M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$32.4M |
| 3 |
TA
Teachers Advisors
New York
|
-$31.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$30.3M |
| 5 |
BlackRock
New York
|
-$27.1M |
SNY Hedge Fund Activity: Q4 2018 in Review
500 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q4 2018, worth a combined $7.77B — down 2.2% from $7.95B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new SNY positions and 52 closed out — a net gain of 25 holders — while 135 added to existing stakes and 185 trimmed.
The largest buyer was Barrow, Hanley, Mewhinney & Strauss, adding an estimated $90M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $52M.
- 500 institutional investors held Sanofi (SNY) as of Q4 2018, up from 480 in Q3 2018.
- Funds reported $7.77B of Sanofi stock for Q4 2018, down 2.2% quarter-over-quarter.
- 77 funds opened new Sanofi positions in Q4 2018 and 52 closed out, a net change of +25 holders.
- The largest Sanofi buyer in Q4 2018 was Barrow, Hanley, Mewhinney & Strauss, an estimated $90M added.
- The largest Sanofi seller in Q4 2018 was Hotchkis & Wiley Capital Management, an estimated $52M sold.
Based on aggregated 13F filings for Q4 2018.